These potent autophagy inhibitors show strong promise for significantly reducing tumor survival and progression.
These peptides are derived from diaphanous-related formins that activate actin polymerization in mammalian cells. Potential applications include the following uses: as a novel anti-cancer therapeutic drug, as a research tool to study cell signaling, structure and physiology, as a novel in vivo model for testing the biochemical activity of small GTPases, and as a reporter for intracellular activation of small GTPases.
This method of norrin protein production makes large-scale protein generation more cost effective, increasing the viability of using norrin as an anti-angiogenic therapeutic agent.
These human Fab and scFv fragments are specific to the human MET extracellular domain and are internalized upon receptor binding. Potential applications include radioimmunotherapy and use as a carrier for delivering potent chemotherapeutics to MET-expressing tumors.
MET siRNA inhibits cancer cell growth, invasion and tumorigenicity. This technology could serve as a potential alternative to chemotherapy as well as a research tool to study MET-associated signaling pathways and mechanisms.
These innovative peptides bind and activate the PTH/PTHrP receptor (PTH1R). Potential applications include use as a tool for designing selective PTH1R-binding molecules and as a treatment option for osteoporosis.